retlirafusp alfa

Overview

Retlirafusp alfa (bintrafusp alfa) is an investigational bifunctional fusion protein that combines anti-PD-L1 (CD274) antibody activity with a TGF-β trap (targeting TGF-β signaling). It is evaluated in nasopharyngeal carcinoma (NPC).

Evidence in the corpus

• Bintrafusp alfa (PD-L1×TGF-β bispecific) monotherapy in R/M NPC (NCT04396886, n=38): ORR 23.7%; median OS 17.0 months; median PFS 2.3 months; concerning safety profile including bleeding, anemia, and hyper-progression in platinum-refractory patients; grade ≥3 TRAE 42.4% PMID:24952746.

Resistance mechanisms

Cancer types (linked)

• NPC

Sources

This page was processed by entity-page-writer on 2026-05-11.